Company Filing History:
4 out of 6 
2 out of 2 
1 out of 1 Years Active: 2017-2022
Title: Inventor Spotlight: Katherine E Keating - Pioneering Cancer Diagnostics Innovations
Introduction: Katherine E Keating is a trailblazing inventor hailing from Magherafelt, GB, known for her groundbreaking work in the field of cancer diagnostics. With a total of 8 patents to her name, Katherine is at the forefront of driving innovation in the healthcare industry, particularly in identifying cancer subtypes for tailored treatment approaches.
Latest Patents: Katherine's most recent patents showcase her dedication to enhancing cancer therapies through precision medicine. One notable patent is the 'Gene signature for immune therapies in cancer,' which enables the stratification of cancer patients for specific immune therapies based on their immune response subtype associated with DNA damage. Another significant patent is the 'Molecular diagnostic test for cancer,' designed to identify cancer subtypes with alterations in biomarker expression related to angiogenesis, aiding in predicting patient response to anti-angiogenic treatments.
Career Highlights: Throughout her illustrious career, Katherine E Keating has made significant contributions to the field of cancer diagnostics. Having worked at leading companies such as Almac Diagnostics Limited and Almac Diagnostic Services Limited, she has spearheaded initiatives that have revolutionized how cancer is diagnosed and treated. Her focus on personalized medicine has set new standards in precision oncology.
Collaborations: Collaborating with esteemed professionals in the industry, Katherine has been part of pioneering research alongside individuals like Denis Paul Harkin and Fionnuala Patterson. Together, they have pushed the boundaries of cancer diagnostics, paving the way for more effective and targeted treatment options for patients worldwide.
Conclusion: Katherine E Keating's relentless dedication to advancing cancer diagnostics through innovative patents underscores her commitment to improving patient outcomes in oncology. Her unique insights and collaborative efforts continue to shape the future of precision medicine, making her a true visionary in the field of healthcare innovation.